Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) has announced the launch of its Ketamine for Chronic and Serious Medical Illness Program which will be introduced first at its clinics in Utah, British Columbia and Quebec.
The program will offer ketamine-assisted therapy alongside additional community support, focusing on improving patients’ physical, emotional, mental and spiritual suffering caused by illness. Healthcare professionals specifically trained in chronic and serious medical illness will provide the care and work with each patient's existing healthcare team to ensure they receive an integrated experience.
"Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain. In the US alone, six million people could benefit from palliative care, but current treatments have gaps that leave patients struggling to cope with distress," Dr Neil Barclay, VP, Product and Protocol Development at Numinus said in a statement.
"Numinus' program addresses this gap by providing safe, evidence-based ketamine-assisted therapy that is specifically designed for this patient population and serves as an adjunct to patients' existing treatment," he added.
READ: Numinus Wellness develops psilocybin-infused tea bag for use in psychedelic research
The company said it intends to expand the program to other clinics in later months.
"Many patients develop adjustment disorders, including depression and anxiety, as they go through the various stages of chronic and serious medical illness," said Dr Paul Thielking, chief science officer at Numinus. "Ketamine-assisted therapy has significant evidence showing efficacy in addressing these symptoms, and Numinus recognizes the opportunity to alleviate suffering while expanding our model of accessible care to more populations."
Numinus also said it is presenting the Salt Lake City premiere of 'Dosed 2: Trip of a Lifetime' on November 8, 2022 -- a documentary following the journey of a patient undergoing psychedelic-assisted therapy to treat end-of-life distress.
Additionally, Numinus said integration has continued as planned after its acquisition of Novamind earlier in 2022, including the latest consolidation of the Murray and Salt Lake City clinics to streamline operations.
Numinus helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
Contact the author at jon.hopkins@proactiveinvestors.com